At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Responsivity and Reproducibility of Messenger and Micro RNA Airway Inflammatory Markers - a Pilot Study
In Brief
An observational study for COPD and COPD Exacerbation. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This study investigates cytokine Messenger (mRNA) and microRNA (miRNA) level expression of interleukin (IL) -6, IL-8, IL-17, tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1 beta and transforming growth factor (TGF)-beta regarding their reproducibility and responsivity in induced sputum and nasal mucosa of patients with chronic obstructive pulmonary disease (COPD) in order to assess their potential as a biomarker outcome measure.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, COPD Exacerbation
CountriesNetherlands
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedApr 2019
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedApr 23, 2019
Enrollment StartNov 14, 2017
Primary CompletionFeb 27, 2021
Study CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.2 years ago